EATRIS-Connect
Project/agreement No.
101130349.
Project funding
5 M€, of which UEF’s share is 236000 EUR.
Project manager
Staff Scientist Petri Mäkinen.
Project timeline
01.05.2024. – 30.04.2027.
Aim
The overall goal is to use Digital Transformation (DT) to improve the early stages of Personalised Medicine development with following objectives:
1. Ensure that EATRIS can provide digital services to improve translational research
2. Adapt EATRIS’ digital services and tools for clinical decision-making
3. Evolve how EATRIS works so it fits better with what countries want for their research
4. Work with other European Research Infrastructures to find complementarities and synergies and make sure we’re all using digital tools in the best way possible
5. Enable a more connected and efficient Personalize Medicine ecosystem
Description
EATRIS-CONNECT is an EU-funded initiative that utilizes digital transformation to accelerate translational medicine. Led by EATRIS and with Horizon Europe budget of €3.9 million, this three-year project (May 2024-April 2027) brings together 21 organizations from across Europe. The project focuses on cross-border alignment and equipping the infrastructure with new digital capacities with a particular focus on AI-enabled technologies, advancing digital readiness while promoting environmentally sustainable digital transformation. This project aligns with commitment to the Digital Europe Programme’s goal of making Europe both greener and more digital.
Lead partner
EATRIS ERIC (Netherlands).
Project partners
Servicio Madrileño de Salud (Spain), Palacký University Olomouc (Czechia), xxxx (Latvija), Zagreb Medical School (Croatia), Istituto Superiore di Sanita (Italy), INFARMED – Autoridade Nacional do Medicamento e Produtos de Saúde, I.P. (Portugal), Luxembourg Institute of Health (Luxembourg), University of Ljubljana (Slovenia), Sofia University St. Kliment Ohridski (Bulgaria), Universitetet I Oslo (Norway), Uppsala University (Sweden), Commissariat à l’énergie atomique et aux énergies alternatives (France), University of Eastern Finland, (Finland), University of Helsinki (Finland), Stichting Health-ri (Netherlands), IRCCS Istituto di ricerche farmacologiche Mario Negri (Italy), Aibili Associacao Para (Portugal), The Provost, Fellows, Foundation Scholars, and other members of Board, of the College of the Holy and Undivided Trinity of Queen Elizabeth near Dublin (Ireland), Fundacio Hospital Universitari Vall d’Hebron – Institut de Recerca (Spain).